Accenture Puts Data Science to Work for Pediatric Leukemia Research
23 Septiembre 2020 - 7:59AM
Business Wire
Accenture (NYSE: ACN) today announced that it has built a data
and analytics approach to manage and derive insights from pediatric
acute myeloid leukemia (AML) genomic data. Working in collaboration
with researchers and clinicians from Fred Hutchinson Cancer
Research Center (Fred Hutch), and the Target Pediatric AML (TpAML)
computational working group, a large-scale research project which
supplied the data, this new approach aims to enable pediatric
oncology physicians and researchers — specifically those focused on
pediatric AML — to better analyze patient clinical trial and
genetic data, with the potential to improve precision medicine.
In collaboration with the TpAML investigators, led by Dr. Soheil
Meshinchi at Fred Hutch, Accenture data scientists aggregated and
standardized anonymized genomic and clinical data from over 2,000
children with AML, treated in clinical trials. RNA data alone, one
of the most critical indicators of treatment outcomes in precision
medicine, amounts to over 48,000 columns per patient if managed in
a standard table format. Combined with other relevant data points —
such as patient demographics, clinical treatment arm, and prognosis
— the sheer volume and variety of combinations presents a
significant hurdle to comparing patient profiles and outcomes at
scale.
“The Accenture data scientists who worked with the TpAML team
had the clinical and genomic background knowledge to hit the ground
running. We model this type of collaboration in all of our
engagements so that we’re able to anticipate challenges and
navigate them with speed,” said Joe Depa, a managing director for
Accenture Applied Intelligence. “In this case particularly, I am
pleased that we were able to leverage the power of data and
analytics to make this information more accessible to researchers,
potentially advancing precision medicine and helping improve
people’s lives.”
Through this engagement, TpAML investigators provided access to
the sequencing data and guidance on key data points — including
genetic markers, clinical trial treatment details, and clinical
outcomes — that can define a patient’s response to a particular
treatment at the time of diagnosis (prior to the start of
chemotherapy). These insights could help inform the recommended
course of treatment, giving patients and physicians a more robust
view of likely clinical success and side effects with standard
therapy, based on an individual patient’s genetic makeup and
medical history. This approach may provide a more informed pathway
to more effective precision medicine for pediatric AML, where
therapy might be modified based on patients’ predicted response to
standard therapy – i.e., high-risk patients may be allocated to
bone marrow transplantation or targeted therapies.
“Integration of genomic and clinical data and getting it into a
usable, accessible format is a significant challenge in precision
medicine,” said Dr. Meshinchi. “This collaborative effort between
TpAML investigators and Accenture data scientists provides a
mechanism to more informed analysis of clinical and genomic data,
and could help identify patients at high risk of failure with
conventional treatments. Validation of these findings can help
modify patients’ treatments based on their relapse risk.”
By applying data science and engineering tools, such as Alteryx
and Python, and machine learning libraries like scikit-learn, to
this corpus of information, Accenture was able to create a code
base that clinicians are using to model, understand and potentially
predict how patients may respond to specific treatments. Data was
made further accessible and consumable using Unity 3D
visualization, offering a more interactive way to view the data in
a game-space environment, laying a foundation for advanced, dynamic
visualizations and VR experiences which could help clinicians
potentially identify anomalies, or which they could use as an
interface to present findings.
“For years, patients diagnosed with a disease often received the
same treatment. And for some people, that treatment worked.
However, for others, it did not work – or did so only marginally,
or with serious side effects. With genome mapping, in combination
with new analytical, scientific and technological advances, it is
possible to develop targeted, more precise, personalized treatments
for individuals or similar patient populations,” explained Stuart
Henderson, global Life Sciences lead for Accenture. “Precision
oncology is delivering on the promise of better patient care and
health outcomes in remarkable ways and we look forward to seeing
more projects like this TpAML investigation.”
This project builds on Accenture research underscoring the
importance of data management and sharing to drive precision
oncology, and the role of data and genomics in biopharmaceutical
development.
About Accenture
Accenture is a leading global professional services company,
providing a broad range of services in strategy and consulting,
interactive, technology and operations, with digital capabilities
across all of these services. We combine unmatched experience and
specialized capabilities across more than 40 industries — powered
by the world’s largest network of Advanced Technology and
Intelligent Operations centers. With 513,000 people serving clients
in more than 120 countries, Accenture brings continuous innovation
to help clients improve their performance and create lasting value
across their enterprises. Visit us at www.accenture.com.
Applied Intelligence is Accenture’s approach to scaling AI for
our clients. We embed AI-powered data, analytics and automation
capabilities into business workflows to accelerate time to value.
Our expertise in defining end-to-end strategy, combined with deep
data infrastructure capabilities, cognitive services and
industrialized accelerators help smooth clients’ path to AI
adoption, extending human capabilities and supporting clients in
scaling AI responsibly. Recognized as a leader by industry
analysts, we collaborate with a powerful global alliance,
innovation and delivery network to help clients deploy and scale AI
within any market and industry. Follow @AccentureAI and visit
www.accenture.com/appliedintelligence.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200923005084/en/
Kathryn Rosati Accenture Applied Intelligence +1 917 452 6662
kathryn.rosati@accenture.com
Accenture (NYSE:ACN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Accenture (NYSE:ACN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024